Here are the 10-K annual reports from Rallybio Corporation (RLYB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow RLYB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RLYB filings page.
Rallybio Corporation files its annual report describing a clinical-stage rare disease pipeline and a planned all‑stock merger with Candid Therapeutics. The deal includes a $505.5 million concurrent financing into Candid and complex exchange ratios that will significantly reshape ownership.
On a pro forma fully diluted basis, Candid equityholders are expected to own about 57.55% of the combined company, Rallybio pre‑merger holders about 3.65%, and concurrent financing investors about 38.80%, subject to net cash and other adjustments. Existing Rallybio holders will also receive contingent value rights tied to future monetization of Rallybio’s legacy assets, including payments from Recursion under a 2025 ENPP1 program sale.
The report highlights lead C5 inhibitor RLYB116, which showed complete and sustained complement inhibition in a 2025 Phase 1 multiple‑ascending‑dose trial, and preclinical iron‑overload antibody RLYB332. Rallybio notes prior collaborations, asset sales, and an ongoing strategic shift toward the Candid autoimmune T‑cell engager platform while winding down certain general and administrative functions.